Loading
Life sciences · Journal article
Journal of Experimental & Clinical Cancer Research · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Management of advanced solid cancers remains challenging, particularly after the development of therapeutic resistance. Here, we synthesized a library of phosphonium-substituted 5-fluorouracil (5-FU) derivatives and evaluated their anticancer activity across multiple tumor models. Among fourteen compounds, EB-18 emerged as the lead candidate, displaying sub-micromolar cytotoxicity in both androgen receptor (AR)-negative PC-3 and AR-positive C4-2 castration-resistant prostate cancer (CRPC) cells and activity across several other malignant solid-tumor cell lines. EB-18 inhibited proliferation, migration, and three-dimensional spheroid growth and induced cell-cycle perturbation and apoptosis. Mechanistic studies in vitro showed that EB-18 disrupted HSP27-associated survival signaling, promoted ubiquitination and proteasome-dependent degradation of DDX5, and suppressed AKT/mTOR signaling. In addition, EB-18 also increased γ-H2AX and reduced Ku70/Ku80 expression, consistent with perturbation of the DNA damage response. AR downregulation was additionally observed in AR-positive C4-2 cells. EB-18 retained activity in patient-derived organoids and multidrug-resistant CRPC cells and significantly inhibited tumor growth in PC-3 xenografts. Collectively, these findings identify EB-18 as a promising anticancer candidate with activity in treatment-resistant CRPC and provide a rationale for further pharmacological, mechanistic, and translational evaluation. Graphical Abstract EB-18, a novel 5-FU derivative, demonstrates superior anticancer activity compared with 5-FU and clinically used chemotherapies (Docetaxel, Cabazitaxel, and Mitoxantrone) across multiple preclinical models, including 2D/3D CRPC cell models, prostate cancer patient-derived organoids, PC-3 xenografts, and multidrug-resistant PC-3 cells, supporting its potential to overcome acquired drug resistance. Mechanistically, EB-18 exerts multifaceted antitumor effects by disrupting the HSP27/DDX5 axis and DNA damage-response machinery, promoting DNA damage and apoptosis, while suppressing AKT/mTOR prosurvival signaling. In AR-positive CRPC cells, EB-18 additionally reduces AR expression. Together, these effects inhibit cancer cell proliferation and survival and support EB-18 as a promising therapeutic candidate for treatment-resistant cancer.